|
Publication Category
I. Clinical Trials
II. Tumour Biology
III. Preclinical/Methods
Highlights
-Use of primary human pancreatic tumour xenografts to test targeted therapy
-Pharmacodynamic monitoring of therapy in peripheral blood
Back to top
|
I. Clinical Trials
Zhu CQ, Santos GC, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(26):4268-4275,2008.
Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist RS, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib. J Pharmacogenetics 8(2):129-38,2008.
Agulnik M, da Cunha-Santos G, Hedley D, Nicklee T, Pintor dos Reis P, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire J, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS.Predictive and pharmacodynamic biomarkers studies in tumor and skin tissue samples of patient with recurrent or metastatic squamous cell carcinoma of the head and neck treated by erlotinib. Journal of Clinical Oncology 25: 2184-2190, 2007.
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25(25):3978-84,2007.
Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25(33):5240-7,2007.
Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S, Pond GR, Dancey JE, Oza AM. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium.Gynecol Oncol 106(2):305-10,2007.
Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25(16):2178-83.
Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136-43,2006.
Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen, S, Tsao MS, Hedley D, Siu LL.
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br.J.Cancer 95:1148-54,2006.
Tong FK, Chow S, Hedley DW.Pharmacodynamic Monitoring of BAY 43-9006 (Sorafenib) in Phase I Clinical Trials Involving Solid Tumor and AML/MDS Patients, using Flow Cytometry to Monitor Activation of the ERK Pathway in Peripheral Blood Cells. Cytometry B 70:107-114),2006.
Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 34(9):1183-91,2006.
Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu LL, Moore M, Oza A.A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor Bortezomib in patients with metastatic colorectal cancer.Clin. Cancer Res. 11:5526-33,2005.
II. Tumour Biology
Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.J Thorac Oncol, 3(5):527-9, 2008.
Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A 105(29):10155-60,2008.
Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ, Shepherd FA, Jurisica I, Der SD, Tsao MS. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25(35):5562-9,2007.
Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest 87(12):1206-17,2007.
Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.Br J Cancer 94(10):1452-9,2006.
Hedley DW, Nicklee T, Moreno-Merlo F, Pintilie M, Fyles A, Milosevic M, Hill R.
Relations Between Non-Protein Sulfydryl Levels In The Nucleus And Cytoplasm, Tumor Oxygenation, And Clinical Outcome Of Patients With Uterine Cervical Carcinoma. International Journal of Radiation Oncology, Biology, and Physics 61:137-144,2005.
Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, Milosevic M, Hill R. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.Clin Cancer Res 9(15):5666-74,2003.
III. Preclinical/Methods
Cao P, Maira SM, García-Echeverría C, Hedley DW.Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.Br J Cancer, 100(8):1267-76, 2009.
Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.Cancer Epidemiol Biomarkers Prev. 17(1):204-11, 2008.
Hedley DW, Chow S, Goolsby C, Shankey TV.Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.Toxicol Pathol, 36; 133, 2008.
Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S.Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn, 9: 421-430,2007.
Schwock, J., Ho, JC, Luther, E., Hedley DW, Geddie, WR. Detection and measurement of phosphorylated signaling proteins in solid tumor fine-needle biopsies by laser-scanning cytometry. Diagnostic Molecular Pathology 16(3):130-40,2007.
Pham, N-A, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao, MS, Ho J, Hedley DW.
Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagnostic Pathology 2(8): 2-8,2007.
Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007;67(4):1735-43.
Birle DC, Hedley DW. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Molecular Cancer Therapeutics 5:2494-2502,2006.
Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations.Cytometry A 67:4-17,2005.
Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth M, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia. Elucidating mechanisms of hypoxia-induced genetic instability. Ann NY Acad Sci 1059:184-195,2005.
Constantinou P, Nicklee T, Hedley DW, Damaskinos S, Wilson BC. A high resolution MACROscope with differential phase contrast, transmitted light, confocal fluorescence, and hyperspectral capabilities for large-area tissue imaging. IEEE Journal of Selected Topics in Quantum Electronics 11:766-777,2005.
Yau CYF, Wheeler J, Sutton K, Hedley DW. Inhibition of Integrin-Linked Kinase (ILK) by QLT0254 Inhibits Akt-Dependent Signaling Pathways and is Growth Inhibitory in Orthotopic Primary Pancreatic Cancer Xenografts. Cancer Research 65:1497-1504,2005
Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol.19:8504-18,2004.
|
